Leukemia

Chronic lymphocytic leukemia (CLL) is a type of blood cancer. Some patients with CLL may not need treatment right away, whereas others require more urgent attention. How do cancer specialists decide when to start patients on therapy? Read More ›

There are important changes to beneficiaries’ Medicare Part D prescription drug coverage for 2020. These changes can affect how much patients must pay out of pocket for their medications, including certain cancer drugs. Read More ›

In an updated analysis of 134 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who were treated with acalabrutinib monotherapy, more than 90% were still responding after 41 months of treatment. Read More ›

Patients with chronic lymphocytic leukemia or mantle-cell lymphoma who were started on acalabrutinib in the United States had high rates of comorbid hypertension and other hematologic malignancies, and about two-thirds received prior ibrutinib. Read More ›

In shared decision-making, patients communicate their preferences and values to their healthcare team when treatment decisions are made. Patients who take an active role in the process tend to be more satisfied with their quality of care. Read More ›

Oral medications are being used increasingly in cancer treatment plans and are more convenient to take compared with medications administered in the doctor’s office or hospital. Oral treatments, however, have their own set of challenges that require effective communication between the patient and the healthcare team. Read More ›